All News

Combined ipilimumab and nivolumab treatment produced durable responses in patients with melanoma brain metastases.

The cumulative economic toll that breast cancer treatment has on survivors and their families carries long-term financial implications, according to a recent study in the Journal of Supportive Care and Cancer.

Supplementing a commonly used treatment approach with an additional inhibitor could help overcome resistance in glioblastoma.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Final approval for Sympazan, the oral soluble film formulation of clobazam, is pending the expiration of the orphan drug exclusivity period for ONFI.

The sugar-removing enzyme may lessen the demand for universal blood donors.

Being accepted into pharmacy school is a great milestone, and the journey was likely filled with hard work and dedication.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

Survivors of breast cancer and their families face long-term cumulative financial implications from treatment and associated costs.

The results of the randomized double-blind study, published in the Journal of Drugs in Dermatology, included 120 women with sensitive skin who suffer from clinically diagnosed rosacea, atopic dermatitis/eczema, or cosmetic intolerance

Opioid related overdoses made up 66.4% of the 63,632 overdose deaths in the United States in 2016, prompting the CDC to gather data on fatal opioid overdoses and a prevention plan.

One lot of Montelukast Sodium Tablets is being voluntarily recalled by Camber Pharmaceuticals, due to a safety risk for consumers.

Even as market disruptors such as Amazon raise concerns, pharmacies prove that the services they provide yield valuable patient experiences.

Officials with the FDA approved Merck’s doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) tablet and doravirine (Pifeltro) for the treatment of HIV-1.

A look at last week's top stories in the world of pharmacy.

Combining pembrolizumab (Keytruda) and an investigational drug could benefit patients with advanced melanoma who have not responded to immunotherapy treatment.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Officials with the FDA have approved Bayer’s antihemophilic factor [recombinant] PEGylated-aucl, BAY94-9027 (Jivi), for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older

The approvals of Delstrigo and Pifeltro are based on findings from 2 phase 3 clinical trials.

The approvals of Delstrigo and Pifeltro are based on findings from 2 phase 3 clinical trials.

Medicare Part D plans will be given flexibility to tailor on-formulary drug coverage based on specific indications.

Officials with the FDA have approved Bayer’s antihemophilic factor [recombinant] PEGylated-aucl, BAY94-9027 (Jivi), for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.

Food products prepared by adding liquid nitrogen at the point of sale, immediately before consumption, have the potential for serious injury, and the FDA is advising consumers to avoid eating, drinking, or handling these products.

BAY94-9027 (Jivi) is approved for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.

Cannabidiol treatment increased the production of inflammatory suppressor cells in mice, which reduced the clinical signs of MS.

Study highlights the importance of understanding, addressing, and bridging gaps in achieving viral suppression.

Top news of the day from across the health care landscape.